Rani Therapeutics announced that it has expanded its partnership with Celltrion to develop an orally administered adalimumab biosimilar RT-105, following their previous collaboration on an ustekinumab biosimilar. The partnership allows Rani to use Celltrion’s adalimumab biosimilar drug substance (CT-P17) exclusively for the development and commercialisation of RT-105. Celltrion will have the option to acquire worldwide rights to RT-105 after a phase I study.
Rani developed the RaniPill® capsule, an oral delivery technology which intends to replace subcutaneous or intravenous injection of biologics and drugs. This is the first announced partnership for a program involving the RaniPill® HC, a high-capacity device in preclinical testing that delivers 20mg of payload with high bioavailability.
Print Page Mail Article